Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Randomized, Cross-over Design, Phase 1 Pharmacodynamic Study to Investigate the Effect of Different Formulations of AZD3355 for the Development of Paresthesiae After Dosing in Healthy Subjects

NCT00688402 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00688402
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00688402 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Randomized, Cross-over Design, Phase 1 Pharmacodynamic Study to Investigate the Effect of Different Formulations of AZD3355 for the Development of Paresthesiae After Dosing in Healthy Subjects
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2008
Completion date
June 30, 2008
Enrollment
48 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastroesophageal reflux disease